ArticleBMC bioinformatics2021
Combining genetic algorithm with machine learning strategies for designing potent antimicrobial peptides.
Article in BMC bioinformatics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.
- Chronic Infections as Catalysts for Melanoma Aggressiveness: Insights into Tumour Microenvironment Modulation.Asian Pacific journal of cancer prevention : APJCP · 2025Pooled it
- Revolutionizing orthopedic healthcare: a systematic review unveiling recombinant antimicrobial peptides.Frontiers in microbiology · 2024Pooled it
- AI for bioactive materials: From material design to biological applications.Bioactive materials · 2026Review
- Embrace Disorder as a Function: Bio-Informed Biomaterials Design Advanced by Intrinsically Disordered Proteins.Biomimetics (Basel, Switzerland) · 2026Article
- Lipidomic Profile Reconstruction of Therapeutic Membrane Targets Using Physics-Based Optimization with Limited Activity Data.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Linker Design in Antibody-Drug Conjugates: Balancing Stability and Drug Release.Pharmaceutics · 2026Review
- Design of Multifunctional Bioactive Peptides for Potential Application in Food Packaging: A Machine-Learning-Integrated Optimization Framework.ACS omega · 2026Article
- AI-Driven Discovery and Design of Antimicrobial Peptides: Progress, Challenges, and Opportunities.Probiotics and antimicrobial proteins · 2026Review
- Artificial Intelligence as a Catalyst for Antimicrobial Discovery: From Predictive Models to De Novo Design.Microorganisms · 2026Review
- Modulating silver diamine fluoride chemical derivatives by solid-binding peptides.Frontiers in bioengineering and biotechnology · 2026Article
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- A Multi-Property Optimizing Generative Adversarial Network for de novo Antimicrobial Peptide Design.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- A deep reinforcement learning platform for antibiotic discovery.bioRxiv : the preprint server for biology · 2025Article
- Lead Informed Artificial Intelligence Mining of Antitubercular Host Defense Peptides.Biomacromolecules · 2025Article
- A review on the screening methods for the discovery of natural antimicrobial peptides.Journal of pharmaceutical analysis · 2025Review
- Machine learning for predictingBioinformation · 2025Article
- Therapeutic peptide development revolutionized: Harnessing the power of artificial intelligence for drug discovery.Heliyon · 2024Review
- Recent Progress in Terrestrial Biota Derived Antibacterial Agents for Medical Applications.Molecules (Basel, Switzerland) · 2024Review
- Antimicrobial Peptide Identified via Machine Learning Presents Both Potent Antibacterial Properties and Low Toxicity toward Human Cells.Microorganisms · 2024Article
- Identification and Design of Novel Potential Antimicrobial Peptides Targeting Mycobacterial Protein Kinase PknB.The protein journal · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundCurrent methods in machine learning provide approaches for solving challenging, multiple constraint design problems. While deep learning and related neural networking methods have state-of-the-art performance, their vulnerability in decision making processes leading to irrational outcomes is a major concern for their implementation. With the rising antibiotic resistance, antimicrobial peptides (AMPs) have increasingly gained attention as novel therapeutic agents. This challenging design problem requires peptides which meet the multiple constraints of limiting drug-resistance in bacteria, preventing secondary infections from imbalanced microbial flora, and avoiding immune system suppression. AMPs offer a promising, bioinspired design space to targeting antimicrobial activity, but their versatility also requires the curated selection from a combinatorial sequence space. This space is too large for brute-force methods or currently known rational design approaches outside of machine learning. While there has been progress in using the design space to more effectively target AMP activity, a widely applicable approach has been elusive. The lack of transparency in machine learning has limited the advancement of scientific knowledge of how AMPs are related among each other, and the lack of general applicability for fully rational approaches has limited a broader understanding of the design space.
methodsHere we combined an evolutionary method with rough set theory, a transparent machine learning approach, for designing antimicrobial peptides (AMPs). Our method achieves the customization of AMPs using supervised learning boundaries. Our system employs in vitro bacterial assays to measure fitness, codon-representation of peptides to gain flexibility of sequence selection in DNA-space with a genetic algorithm and machine learning to further accelerate the process.
resultsWe use supervised machine learning and a genetic algorithm to find a peptide active against S. epidermidis, a common bacterial strain for implant infections, with an improved aggregation propensity average for an improved ease of synthesis.
conclusionsOur results demonstrate that AMP design can be customized to maintain activity and simplify production. To our knowledge, this is the first time when codon-based genetic algorithms combined with rough set theory methods is used for computational search on peptide sequences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.